Johnson & Johnson's ICOTYDE® (icotrokinra) Shows Significant Improvement in Psoriatic Arthritis in Phase 3 Study

Johnson & Johnson announced positive results from a Phase 3 study investigating ICOTYDE® (icotrokinra) in biologic-naïve adults with active psoriatic arthritis. The targeted oral peptide met its primary endpoint, with 58% of patients achieving an American College of Rheumatology 20 (ACR20) response at Week 16, compared to 41% for placebo. The safety findings were consistent with the established safety profile of ICOTYDE.